The EMBO Journal
 
Advanced search
Journal home
Current issue
Advance Online Publication
Web Focuses
Archive
Browse by subject
Free online sample issue
Aims and scope
Press releases
ToC by email
Authors & Referees
Guide for authors
Submit an Article
Guide for referees
Editorial Team, Senior Advisors and Advisory Editorial Board
Contact Editorial office
Customer services
Subscribe
Order sample copy
Purchase articles
Reprints and permissions
Contact NPG
Advertising
EMBO
www.embo.org
Article
Subject Categories: Genome Stability & Dynamics
The EMBO Journal (2008) 27, 1368–1377, doi:10.1038/emboj.2008.61
Published online 3 April 2008
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
Nicholas C Turner1, Christopher J Lord1, Elizabeth Iorns1, Rachel Brough1, Sally Swift1, Richard Elliott1, Sydonia Rayter1, Andrew N Tutt1, 2 and Alan Ashworth1
1 The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
2 Breakthrough Breast Cancer Research Unit, King's College London School of Medicine, Guy's Hospital, London, UK

To whom correspondence should be addressed
Alan Ashworth, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK. Tel.: +44 0 20 7153 5333; Fax: +44 0 20 7153 5340; E-mail: alan.ashworth@icr.ac.uk

Received 10 September 2007; Accepted 4 March 2008; Published online 3 April 2008.
Abstract
Inhibitors of poly (ADP-ribose)-polymerase-1 (PARP) are highly lethal to cells with deficiencies in BRCA1, BRCA2 or other components of the homologous recombination pathway. This has led to PARP inhibitors entering clinical trials as a potential therapy for cancer in carriers of BRCA1 and BRCA2 mutations. To discover new determinants of sensitivity to these drugs, we performed a PARP-inhibitor synthetic lethal short interfering RNA (siRNA) screen. We identified a number of kinases whose silencing strongly sensitised to PARP inhibitor, including cyclin-dependent kinase 5 (CDK5), MAPK12, PLK3, PNKP, STK22c and STK36. How CDK5 silencing mediates sensitivity was investigated. Previously, CDK5 has been suggested to be active only in a neuronal context, but here we show that CDK5 is required in non-neuronal cells for the DNA-damage response and, in particular, intra-S and G2/M cell-cycle checkpoints. These results highlight the potential of synthetic lethal siRNA screens with chemical inhibitors to define new determinants of sensitivity and potential therapeutic targets.
Keywords: CDK5, cell cycle, DNA repair, poly(ADP)ribose polymerase, RNAi screen
Send to a friendEmail link to a friend
PDFDownload PDF
Full textFull text
Next article
Previous article
Table of contents
rights and permissionsRights and permissions
order commercial reprintsReprints
ToC alertRegister for table of contents by email
  Privacy policy Copyright © 2008 by the European Molecular Biology Organization